CK Life Sciences H1 loss narrows on lower R&D costs

CK Life Sciences Intl (Holdings)

11/08/2026 10:45

Overview
Hong Kong life sciences firm's first half revenue rose yr/yr, loss narrowed 81%
Loss reduction driven by lower R&D expenses after corporate reorganisation
Commercial businesses reported higher revenue but margins pressured by cost increases

Outlook
Company says geopolitical and economic uncertainty will challenge sales and profitability in commercial businesses
CK Life Sciences expects more disciplined R&D execution to help manage expenses
Company expects foundations built over years will help withstand current headwinds

Result Drivers
LOWER R&D EXPENSES - Loss reduction attributed to lower R&D expenses after corporate reorganisation and change in accounting treatment
HIGHER COMMERCIAL REVENUE - Commercial businesses reported higher revenue, though margins were pressured by cost increases
COST PRESSURES - Margins in both nutraceutical and agriculture-related segments were affected by tariffs, inflation, supply chain disruptions, and adverse weather

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
HK$2.72 bln
 

Reuters Recommended Reads
Aug 10 - Perspective Therapeutics Q2 net loss widens on higher R&D costs
Aug 11 - Malaysia’s SD Guthrie sees El Niño impacting 2027-28 palm oil output
Aug 10 - Biohaven Q2 net loss narrows on lower R&D spend

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)